UroGen's UGN-103 demonstrates 94.5% six-month response rate in NMIBC trial, supporting FDA filing planned for Q3 2026.

Senti Bio's SENTI-202 achieves 50% complete remission in Phase 1 relapsed/refractory AML, with responses durable beyond 21 months using...

Regeneron's fianlimab melanoma trial missed its primary endpoint for progression-free survival, though the high-dose combination showed a 5.1-month numerical...

A Phase 2 RCT published in Nature Medicine shows favipiravir cut Lassa fever mortality with HR 0.50—but the regulatory...

SN BioScience begins Phase 1b/2 trial of SNB-101, a nanoparticle SN-38 formulation, in extensive-stage small cell lung cancer patients...

EyePoint's DURAVYU receives third consecutive positive safety review in wet AMD Phase 3 trials, with over 900 randomized patients...

Envudeucitinib achieves 68% PASI 90 response in Phase 3 psoriasis trials, surpassing current oral therapy benchmarks at Week 24.

Cardiff Oncology advances onvansertib Phase 3 for RAS-mutated colorectal cancer after 72.2% response rate in Phase 2 trial.

Biogen's diranersen shows tau biomarker reduction in Phase 2 Alzheimer's study, signaling potential for combination therapy approaches despite missing...

Senti Biosciences gains FDA backing for SENTI-202 donor selection strategy in relapsed/refractory AML, with 50% complete remission rates tied...